Replies to post #14341 on RespireRx Pharmaceuticals Inc (RSPI)

[enemem]

On the slide where the next year was mapped out, Stoll spent a good deal of time discussing the inlicensing bullet, and skipped the M&A bullet. This doesn't look like a high priority.